Algeta
Template:Short description Template:DMCA
Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.
| Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. | |
Company type | Acquired by Bayer AG in December 2013 |
|---|---|
| ISIN | Script error: No such module "WikidataIB". |
| Industry | Script error: No such module "WikidataIB". |
| Predecessor | Script error: No such module "WikidataIB". |
| Incorporated | Script error: No such module "WikidataIB". |
| Founded | Script error: No such module "WikidataIB". |
| Founder | Script error: No such module "WikidataIB". |
| Defunct | Script error: No such module "WikidataIB". |
| Successor | Script error: No such module "WikidataIB". |
| Headquarters | Oslo, Norway |
| Products | Xofigo |
| Revenue | Script error: No such module "WikidataIB". |
| Script error: No such module "WikidataIB". | |
| Script error: No such module "WikidataIB". | |
| Total assets | Script error: No such module "WikidataIB". |
Number of employees | Script error: No such module "WikidataIB". |
| Parent | Script error: No such module "WikidataIB". |
| Website | Bayer.no |
Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".
Algeta ASA (ALGETA:NO) was founded in 1997 by Roy H. Larsen and Øyvind S. Bruland in Oslo, Norway as a private biotechnology and pharmaceutical company.[1] The company’s research and development focus lies in the field of alpha-particle emitting radiopharmaceuticals. The lead product of the company, Xofigo is the first marketed alpha-particle emitting radiopharmaceutics for cancer treatment.[2]
Early fund raising
Algeta raised its series A financing round in 2005 with a total amount of €23 million.[3] The financing round was led by new investors HealthCap, Advent Venture[4] and SR One.[5]
Public offering
In March 2007, the company went public and traded in the Oslo Stock Exchange under the ticker symbol ALGETA and raised $41 million.[6]
Xofigo
Algeta’s lead product Xofigo (radium Ra 223 dichloride, radium-223, previously called Alpharadin) is a radiotherapeutic drug which is supplied as injectable sterile solution. The active ingredient alpha particle emitting isotope radium-223 mimics calcium and forms complexes with hydroxyapatite at areas where increased bone turnover takes place, such as cancer bone metastasis. The product received U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)[7] approval in May 2013 [8] and November 2013,[9] respectively, to treat castration-resistant prostate cancer, symptomatic bone metastases and unknown visceral metastatic disease. The FDA approval was based on a double-blind, randomized, placebo-controlled phase III clinical trial of 809 patients with castration-resistant prostate cancer and symptomatic bone metastases. The trial was designed to measure overall survival. Interim analysis revealed 14 months median overall survival in the Xofigo group as compared to 11.2 months in the placebo group. The data were later confirmed by updated exploratory analysis showing Xofigo improved overall survival.
Algeta Bayer deals
In September 2009, Algeta and Bayer AG anchored a development and commercialization deal for Xofigo with the total deal size of $800 million.[10] In December 2013, Bayer offered a full acquisition of Algeta for $2.9 billion.[11] The largest shareholder HealthCap pre-approved the deal which was completed in March 2014.[12]
References
Page Template:Reflist/styles.css has no content.
- ^ Page Module:Citation/CS1/styles.css has no content."Algeta ASA - Company Profile and News". Bloomberg News.
- ^ Page Module:Citation/CS1/styles.css has no content."Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases". Archived from the original on 14 July 2014. Retrieved 1 July 2014.
- ^ Page Module:Citation/CS1/styles.css has no content."Algeta ASA Raises Euro 23 Million in Series a Round". Archived from the original on 14 July 2014. Retrieved 1 July 2014.
- ^ Page Module:Citation/CS1/styles.css has no content."Stocks". Archived from the original on 17 April 2010.
- ^ Page Module:Citation/CS1/styles.css has no content."Stocks". Archived from the original on 6 December 2008.
- ^ Page Module:Citation/CS1/styles.css has no content."Algeta - Initial Public Offering - Drugs.com MedNews". Archived from the original on 3 March 2016. Retrieved 23 January 2018.
- ^ Page Module:Citation/CS1/styles.css has no content."European Medicines Agency". European Medicines Agency. Retrieved 27 May 2023.
- ^ Page Module:Citation/CS1/styles.css has no content."FDA approves new drug for advanced prostate cancer". Food and Drug Administration. Archived from the original on 4 June 2013. Retrieved 16 December 2019.
- ^ Page Module:Citation/CS1/styles.css has no content."Xofigo". European Medicines Agency. 17 September 2018. Retrieved 27 May 2023.
- ^ Page Module:Citation/CS1/styles.css has no content."Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization... -- re> OSLO, September 3 /PRNewswire-FirstCall/ --". Archived from the original on 14 April 2013.
- ^ Page Module:Citation/CS1/styles.css has no content."Bayer to Acquire Drug Maker Algeta in $2.9 Billion Deal". 19 December 2013.
- ^ Page Module:Citation/CS1/styles.css has no content."BAYNEWS: Bayer completes voluntary takeover offer for Algeta". Archived from the original on 14 July 2014. Retrieved 1 July 2014.
Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.
